Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Shareholder Meeting (June 2020)
13 slides from Vitrolife Ab's shareholder meeting presentation, Jun 15, 2020
Slide 1: Annual General Meeting 15 June 2020
ANNUAL GENERAL MEETING 15 JUNE 2020 Thomas Axelsson, CEO 1
Slide 2: Summary of 2019
SUMMARY OF 2019 2019: Sales of 1 480 MSEK (1 151) equals +29% in SEK Sales increased by 22% in local currency, whereof 12% organic growth EBITDA of 587 MSEK (479) corresponding to a margin of 40% (42) 2
Slide 3: Sales and Growth per Market Region
SALES AND GROWTH PER MARKET REGION SHARE OF VITROLIFE’S SALES 19% 40% 25% 16% ROLLING 12-MONTHS 2019 GROWTH RATE COMPARED TO LAST YEAR IN LOCAL CURRENCIES +51% +12% +17% +31% Total +22%* 3 * Whereof organic growth +12 percent
Slide 4: Sales and Growth per Business Unit
SALES AND GROWTH PER BUSINESS UNIT SEK millions, rolling 12m 1600 125 91 GENOMICS 1400 54 60 58 ART EQUIPMENT -3% 1200 20 54 58 51 1000 78 80 65 61 343 382 431 TIME-LAPSE +37% 297 302 267 282 800 254 271 DISPOSABLE 167 168 176 184 181 DEVICES +2% 148 151 149 153 600 400 545 543 562 584 606 634 644 6
Slide 5: Investments in Future Growth
INVESTMENTS IN FUTURE GROWTH Acquisition and collaboration agreement regarding technology for embryo assessment using AI. Successful transfer of customers from Illumina and new organisation in place. Development project started. Acquisition of UK & Ireland distributor strengthens Launch of new produ
Slide 6: AI for Embryo Selection
Al FOR EMBRYO SELECTION 6 Vitrolife 7%
Slide 7: Key Financials Group 2019
KEY FINANCIALS GROUP 2019 • Fluctuations in exchange rates positively impacted EBITDA by 37 MSEK. • EBITDA margin improved by approximately 1 percentage point due to IFRS 16. • EBITDA margin was negatively impacted by product mix (Genomics) and obsolescence costs. 2019 2018 FY FY Sales, MSEK 1 480 1
Slide 8: The Most Important Sustainability Aspects
THE MOST IMPORTANT SUSTAINABILITY ASPECTS Vitrolife’s Board and management have carried out a materiality analysis and identified a number of sustainability factors that are important for Vitrolife’s long-term competitiveness and profitability and which support the UN’s global objectives for sustain
Slide 9: The Share
THE SHARE • Listed on NASDAQ Stockholm Large Cap • Market value: ~21 billion SEK LARGEST OWNERS 31 May 2020 1. William Demant Invest A/S 26.1% 2. Bure Equity AB (publ) 19.0% 3. State Street Bank and Trust Co 13.2% 4. BNY Mellon SA/NV 2.4% 5. Lannebo Småbolag 2.1% 6. CBNY-Norges Bank 2.0% 9
Slide 10: COVID-19 and Short-term Outlook
COVID-19 AND SHORT-TERM OUTLOOK Vitrolife estimates that sales in the second quarter will amount to about 40-50% of the corresponding period last year in local currency. Since the beginning of April, a slow recovery in the number of IVF treatments in the world has been noted. Sales recovery wi
Slide 11: Outlook
OUTLOOK Long-term market growth 5-10% in monetary terms Expansion of sales Broadening the product offering 11
Slide 12: 12
12
Slide 13: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i